Neoplasms, Glandular and Epithelial clinical trials

The registry lists 71 studies for Neoplasms, Glandular and Epithelial across more than 10 countries. 14 are recruiting or about to start. 8 of them are mainly about Neoplasms, Glandular and Epithelial (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its 90 narrower conditions too, such as Carcinoma, Hepatocellular: 19,867 studies, 5,113 open.

Get an email when these change. Save the Neoplasms, Glandular and Epithelial studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 29
Recruiting: 12
Terminated: 11
Status unknown: 9
Active, not recruiting: 6
Approved for marketing: 1

Phase

Phase 2: 31
Phase 1: 18
Phase 3: 7

Where

United States: 33
China: 14
France: 9
Spain: 7
Germany: 7
Singapore: 7

Who runs them

Sumitomo Pharma America, Inc. (3) · Boston Scientific Corporation (3) · Royal Marsden NHS Foundation Trust (3) · Revolution Medicines, Inc. (2) · Syndax Pharmaceuticals (2) · National Cancer Institute (NCI) (2) · Catalysis SL (2) · Xiaoxiang Chen (2)

What is being tested here

Drugs under test in Neoplasms, Glandular and Epithelial studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	All
Lenvatinib	2	2
Cisplatin	1	2
Ocoxin	1	2
Carboplatin	1	2
Adjuvant	1	1
Nogapendekin alfa inbakicept	1	1
Ordastobart	1	1
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915	1	1
G 207	1	1
Oncolytic HSV-1 G207	1	1

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open · Angiogenesis inhibitors 4 · Antimitotic agents 4

Coming up

0phase 3 studies under way

5studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5

Dec 2026Sub-type Specific Genomic Mutations in sBOTs · Universitair Ziekenhuis Brussel
Jan 2027Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Colorectal Laterally Spreading Lesions. · José Carlos Marín Gabriel
Jun 2027TheraSphere With Durvalumab and Tremelimumab for HCC · Boston Scientific Corporation
Jun 2027TheraSphere Japan Pre-Market Study · Boston Scientific Corporation
Jul 2027Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) · National Cancer Institute (NCI)

Who these studies take

Of the 12 Neoplasms, Glandular and Epithelial studies recruiting now, 7 (58%) set no upper age limit and 2 (17%) stop at 75 or younger. 1 (8%) take children under 18. 3 (25%) are for women only and 2 (17%) for men only; 1 (8%) take healthy volunteers.

Recruiting studies that take each age, of 12
Age	Women	Men
10	1 (8%)	1 (8%)
18	9 (75%)	9 (75%)
30	9 (75%)	8 (67%)
40	9 (75%)	8 (67%)
50	9 (75%)	8 (67%)
65	8 (67%)	8 (67%)
75	8 (67%)	8 (67%)
85	7 (58%)	7 (58%)

Across all 71 studies, recruiting or not: 11% stop at 75 or younger and 10% at 65; 8% take children; 24% are for women only and 6% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 15, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 71. Browse all 71 → or search them.